Mar. 20, 2013 (Shareholders Foundation) - An investigation on behalf of investors in Obagi Medical Products, Inc. (NASDAQ:OMPI) shares was announced concerning whether the offer by Valeant Pharmaceuticals International to acquire Obagi Medical Products, Inc. for $19.75 per NASDAQ:OMPI share and the takeover process are unfair to investors in Obagi Medical Products shares.

The investigation by a law firm concerns whether certain officers and directors of Obagi Medical Products, Inc. breached their fiduciary duties owed to NASDAQ:OMPI investors in connection with the proposed acquisition.

On Mar. 20, 2013, Obagi Medical Products, Inc (NASDAQ: OMPI) announced that it entered into a merger agreement with Valeant Pharmaceuticals International, Inc under which Valeant Pharmaceuticals International, Inc will acquire all of the outstanding common stock of Obagi Medical Products, Inc. for $19.75 perNASDAQ:OMPI share in cash.

However, given that at least one analyst has set the high target price for NASDAQ:OMPI shares at $19.00 per share, the investigation a law firm concerns whether the $19.75-offer is too low for NASDAQ:OMPI stockholders. The investigation focuses on whether the Obagi Medical Products Board of Directors undertook an adequate sales process, adequately shopped the company before entering into the transaction, maximized shareholder value by negotiating the best price, and acted in the shareholders' best interests in connection with the proposed sale.
Obagi Medical Products, Inc. (NASDAQ:OMPI) reported that its annual Total Revenue rose form $112.76 million in 2010 to $114.11 million in 2011 and that its respective Net Income increasefr from $9.49 million to $10.02 million.

Shares of Obagi Medical Products, Inc. (NASDAQ:OMPI) grew from $4.05 per share in March 2009 to as high as $17.15 per share in July 2012.

On March 20, 2013, NASDAQ:OMPI shares closed at $19.73 per share.